A Randomized Double-Blind Study of Alpha-Difluromethylornithine (DFMO) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3
OBJECTIVES: I. Compare the efficacy of eflornithine versus placebo in causing regression in
patients with cervical intraepithelial neoplasia. II. Compare the qualitative and
quantitative toxicities of these treatment regimens in these patients. III. Establish the
biochemical tissue markers of DNA content, PCNA, the ras oncogene, EGFR, and keratin and
involucrin as intermediate biomarker end points for squamous carcinogenesis in these
patients.
OUTLINE: This is a randomized, double blind, multicenter study. Patients are randomized to
one of three treatment arms. Arm I-II: Patients receive one of two different doses of oral
eflornithine daily. Arm III: Patients receive oral placebo daily. Treatment continues for 28
days in the absence of disease progression or unacceptable toxicity. Patients are followed
at 28 days, and then at 6, 12, 18, and 24 months.
PROJECTED ACCRUAL: A total of 180 patients (60 per treatment arm) will be accrued for this
study.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Efficacy Comparison of Eflornithine versus Placebo
Efficacy in causing regression in patients with cervical intraepithelial neoplasia measured by absence of disease progression or unacceptable toxicity. Patients are followed at 28 days, and then at 6, 12, 18, and 24 months.
28 Days
No
Michele Follen, MD, PhD
Study Chair
M.D. Anderson Cancer Center
United States: Federal Government
ID92-026
NCT00006079
June 2000
April 2004
Name | Location |
---|---|
University of Texas - MD Anderson Cancer Center | Houston, Texas 77030-4009 |